브랜드 제네릭 시장 : 약제 클래스별, 용도별, 투여 경로별, 유통 채널별, 세계 예측(2023-2032년)

Global Branded Generics Market size will exhibit an appreciable growth rate between 2023 and 2032. Government initiatives aimed at promoting generic products can have a stimulating effect on the market. In September 2023, the Swiss government approved changes to the Ordinance on Health Insurance, the Ordinance on Health Care Services, and the Ordinance on Medicinal Products, scheduled to be implemented on January 1, 2024. These revisions aim to make generic drugs more cost-effective compared to their brand-name counterparts while also raising patients' co-payments for selecting pricier options. This strategic move is designed to achieve annual savings of CHF 250 million, equivalent to $275 million.

By encouraging the use of more affordable generic alternatives, government policies create a competitive environment, prompting pharmaceutical companies to innovate in producing branded generic products. This competition can lead to a wider range of high-quality, cost-effective branded generics, benefiting consumers with increased choices and potentially lower prices in the pharmaceutical market.

The overall branded generics market is categorized based on drug class, application, route of administration, distribution channel, and region.

The cardiovascular disease segment could dominate the application landscape of the branded generics industry by 2032. Patients and healthcare professionals often prefer trusted brand names for critical medications, ensuring reliability and quality. Additionally, branded generics may offer specific formulations or delivery methods that cater to patient preferences and needs. This demand is further propelled by a growing awareness of cardiovascular health and a focus on effective, well-established treatments.

Topical branded generics market will demonstrate a healthy growth rate through 2032. Sales of topical branded generics are on the rise due to their effectiveness, affordability, and familiarity. Consumers trust well-known brand names for skin and healthcare products, making them a preferred choice. Topical branded generics often offer the same quality and performance as their brand-name counterparts at a lower cost, appealing to cost-conscious consumers. The increasing awareness of skin health and the availability of these trusted alternatives contribute to their growing popularity in the market.

Europe branded generics industry is experiencing robust growth due to several key factors. European consumers prioritize quality and trust established brand names for pharmaceuticals, even in generic forms. Additionally, healthcare systems in the region encourage the use of cost-effective generics, benefiting both patients and government budgets. Regulatory frameworks also support the growth of branded generics, creating a favorable environment for pharmaceutical companies to offer these trusted alternatives.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Branded generics industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Drug class trends
  • 2.1.4 Application trends
  • 2.1.5 Route of administration trends
  • 2.1.6 Distribution channel trends

Chapter 3 Branded Generics Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence rate of chronic diseases
    • 3.2.1.2 Rising number of expired patents
    • 3.2.1.3 Increasing government initiatives to promote generic products
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Competition from standard generics and brand-name drugs
    • 3.2.2.2 Regulatory barriers
• 3.3 Growth potential analysis
  • 3.3.1 By drug class
  • 3.3.2 By application
  • 3.3.3 By route of administration
  • 3.3.4 By distribution channel
• 3.4 COVID- 19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Branded Generics Market, By Drug Class, 2018 - 2032 (USD Million)

• 5.1 Key trends, by drug class
• 5.2 Anti-hypertensive
• 5.3 Hormones
• 5.4 Antimetabolites
• 5.5 Anti-depressants
• 5.6 Alkylating agents
• 5.7 Lipid lowering drugs
• 5.8 Anti-epileptics
• 5.9 Anti-psychotics
• 5.10 Other drug classes

Chapter 6 Branded Generics Market, By Application, 2018 - 2032 (USD Million)

• 6.1 Key trends, by application
• 6.2 Oncology
• 6.3 Cardiovascular diseases
• 6.4 Neurological diseases
• 6.5 Gastrointestinal diseases
• 6.6 Dermatological diseases
• 6.7 Acute & chronic pain
• 6.8 Other applications

Chapter 7 Branded Generics Market, By Route of Administration, 2018 - 2032 (USD Million)

• 7.1 Key trends, by route of administration
• 7.2 Oral
• 7.3 Topical
• 7.4 Parenteral
• 7.5 Other routes of administration

Chapter 8 Branded Generics Market, By Distribution Channel, 2018 - 2032 (USD Million)

• 8.1 Key trends, by distribution channel
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Branded Generics Market, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Teva Pharmaceutical Industries Ltd.
• 10.2 Lupin
• 10.3 Sanofi
• 10.4 Sun Pharmaceutical Industries, Ltd.
• 10.5 Dr. Reddy's Laboratories Ltd
• 10.6 Endo International plc
• 10.7 Pfizer, Inc.
• 10.8 Viatris, Inc.
• 10.9 Abbott Laboratories
• 10.10 Sandoz